Evaxion A (EVAX) Non-Current Debt (2021 - 2025)
Evaxion A's (EVAX) quarterly Non-Current Debt came in at $5.3 million in Q4 2025, down 33.23% YoY from $8.0 million in Q4 2024, and down 40.79% on a QoQ basis from $9.0 million in Q2 2025.
Evaxion A (EVAX) Non-Current Debt (2021 - 2025) Analysis & Trends
Evaxion A (EVAX) has 5 years of Non-Current Debt data on file, last reported at $5.3 million in Q4 2025.
- Quarterly Non-Current Debt fell 33.23% year-over-year to $5.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.3 million (down 33.23% YoY) and the FY2025 annual result came in at $5.3 million, down 33.23% from the prior year.
- Non-Current Debt fell to $5.3 million in Q4 2025, from $9.0 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $9.0 million in Q2 2025 to a low of $1.0 million in Q4 2021.
- A 5-year average of $6.6 million and a median of $7.9 million in 2022 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt surged 653.26% — and 2025, when it slumped 33.23%.
- Tracing EVAX's Non-Current Debt over 5 years: stood at $1.0 million in 2021, then surged by 653.26% to $7.9 million in 2022, then advanced by 7.95% to $8.5 million in 2023, then decreased by 5.67% to $8.0 million in 2024, then tumbled by 33.23% to $5.3 million in 2025.
- The last three Non-Current Debt figures came in at $5.3 million (Q4 2025), $9.0 million (Q2 2025), and $8.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 8.96 Bn |
| 10 | Evaxion A | 27.52 Mn | 27.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.35 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Dec 31, 2024 | 8.01 Mn |
| Jun 30, 2024 | 8.26 Mn |
| Dec 31, 2023 | 8.49 Mn |
| Jun 30, 2023 | 8.08 Mn |
| Dec 31, 2022 | 7.86 Mn |
| Jun 30, 2022 | 7.34 Mn |
| Mar 31, 2022 | 7.72 Mn |
| Dec 31, 2021 | 1.04 Mn |
| Sep 30, 2021 | 1.10 Mn |